仁度生物
(688193)
| 流通市值：13.26亿 | | | 总市值：16.80亿 |
| 流通股本：3156.84万 | | | 总股本：4000.00万 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 328,927,414.04 | 261,582,058.68 | 235,075,162.53 | 242,029,282.79 |
| 应收票据及应收账款 | 47,001,938.59 | 49,371,105.29 | 66,139,797.51 | 72,397,506.47 |
| 应收账款 | 47,001,938.59 | 49,371,105.29 | 66,139,797.51 | 72,397,506.47 |
| 应收款项融资 | 638,993.54 | - | - | - |
| 预付款项 | 4,536,204.44 | 5,858,195.71 | 4,534,090.97 | 3,178,498.31 |
| 其他应收款合计 | 1,246,492.25 | 511,462.55 | 1,305,312.87 | 986,103.06 |
| 存货 | 24,509,308.32 | 25,137,015.39 | 24,199,232.67 | 25,185,902.01 |
| 其他流动资产 | 30,141,084.62 | 31,324,883.63 | 83,052,622.83 | 79,603,271.29 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 879,711,213.58 | 884,744,376.81 | 857,082,886.04 | 869,412,855.59 |
| 非流动资产: | | | | |
| 固定资产 | 74,659,220.6 | 77,670,995.92 | 81,000,463.24 | 83,741,005.82 |
| 在建工程 | - | 409,541.28 | - | 218,830.28 |
| 使用权资产 | 3,902,789.17 | 4,142,089.06 | 4,836,903.72 | 5,531,718.39 |
| 无形资产 | 352,303.3 | 409,619.71 | 466,936.12 | 524,252.53 |
| 长期待摊费用 | 7,095,327.7 | 6,739,431.96 | 6,967,344.86 | 7,193,071.1 |
| 递延所得税资产 | 20,908,538.18 | 20,242,265.91 | 13,140,363.09 | 13,471,239.4 |
| 其他非流动资产 | - | - | 41,800,500 | 41,409,165 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 106,918,178.95 | 109,613,943.84 | 148,212,511.03 | 152,089,282.52 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 986,629,392.53 | 994,358,320.65 | 1,005,295,397.07 | 1,021,502,138.11 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 4,608,695.97 | 3,037,835.97 | 5,235,321.77 | 3,819,549.55 |
| 应付账款 | 4,608,695.97 | 3,037,835.97 | 5,235,321.77 | 3,819,549.55 |
| 合同负债 | 4,885,698.08 | 9,012,761.97 | 2,883,172.86 | 3,836,598.68 |
| 应付职工薪酬 | 7,471,116.26 | 11,827,641.91 | 9,297,521.84 | 8,952,662.79 |
| 应交税费 | 2,365,982.59 | 742,833.38 | 1,124,651.6 | 1,048,360.38 |
| 其他应付款合计 | 44,740,897.03 | 47,777,766.98 | 48,065,737.7 | 52,164,219.48 |
| 一年内到期的非流动负债 | 1,129,295.79 | 1,908,493.38 | 2,574,992.71 | 2,911,213.85 |
| 其他流动负债 | 93,254.9 | 107,835.49 | 111,353.36 | 139,822.45 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 65,294,940.62 | 74,415,169.08 | 69,292,751.84 | 72,872,427.18 |
| 非流动负债: | | | | |
| 租赁负债 | 2,890,172.26 | 2,327,989.12 | 2,288,127.64 | 2,796,556.12 |
| 预计负债 | 57,083.13 | 12,111.44 | 31,607.43 | 3,143.54 |
| 递延收益 | 4,962,722.57 | 5,723,677.98 | 6,403,014.5 | 7,210,111.88 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 7,909,977.96 | 8,063,778.54 | 8,722,749.57 | 10,009,811.54 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 73,204,918.58 | 82,478,947.62 | 78,015,501.41 | 82,882,238.72 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 40,000,000 | 40,000,000 | 40,000,000 | 40,000,000 |
| 资本公积 | 777,818,952.15 | 777,440,366.02 | 777,482,092.16 | 776,221,863.73 |
| 减:库存股 | 35,659,786.74 | 35,659,786.74 | 35,659,786.74 | 23,378,565.5 |
| 其他综合收益 | 177,751.26 | 232,167.61 | -763,277.85 | -103,881.17 |
| 盈余公积 | 14,035,318.24 | 14,035,318.24 | 12,924,505.3 | 12,924,505.3 |
| 未分配利润 | 117,052,239.04 | 115,831,307.9 | 133,296,362.79 | 132,955,977.03 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 913,424,473.95 | 911,879,373.03 | 927,279,895.66 | 938,619,899.39 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 913,424,473.95 | 911,879,373.03 | 927,279,895.66 | 938,619,899.39 |
| 负债和股东权益合计 | 986,629,392.53 | 994,358,320.65 | 1,005,295,397.07 | 1,021,502,138.11 |
| 公告日期 | 2025-04-30 | 2025-04-30 | 2024-10-30 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |